Michael A. Sweetland

Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction

John A. Corbett, Ronald G. Tilton, Kathy Chang et al. · Diabetes · 1992 · 611 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans.

John A. Corbett, Michael A. Sweetland, Jaw‐Lin Wang et al. · Proceedings of the National Academy of Sciences · 1993 · 409 citations

Life Sciences, Endocrinology, Immunology +17

Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide.

John A. Corbett, Jaw‐Lin Wang, Michael A. Sweetland et al. · Journal of Clinical Investigation · 1992 · 286 citations · Full text

Life Sciences, Cell Biology, Endocrinology +16

Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-1 beta-induced inhibition of insulin secretion.

John A. Corbett, Jack R. Lancaster, Michael A. Sweetland et al. · Journal of Biological Chemistry · 1991 · 259 citations · Full text

Life Sciences, Biochemistry, Endocrinology +14

Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction

John A. Corbett, Ronald G. Tilton, K. Chang et al. · Diabetes · 1992 · 192 citations

Medicine, Endocrinology, Pharmacology +16